Group 1 - Coinbase's CEO plans to "on-chain" the entire lifecycle of startups from establishment, financing to public listing, aiming for instant financing through smart contracts and USDC transfers [1][3] - The initiative is expected to make capital formation "more efficient, fair, and transparent," potentially increasing the number of companies seeking financing and entrepreneurship [4] - Morgan Stanley has upgraded Coinbase's stock rating to "overweight," reflecting positive market sentiment, with Coinbase's stock price rising approximately 10% [5] Group 2 - To achieve its vision, Coinbase will simplify the current cumbersome financing process using the recently acquired Echo platform, which has helped over 200 projects raise more than $200 million [6][7] - Echo will initially operate independently but will gradually integrate into Coinbase's ecosystem, connecting entrepreneurs seeking funding with Coinbase's $500 billion in managed assets and global investor base [7] - Coinbase is working with U.S. regulators to promote broader access to on-chain financing, challenging existing regulatory frameworks [8][10] Group 3 - Coinbase's on-chain strategy is closely linked to the development of its Layer-2 network, Base, which is a significant reason for investment banks' positive outlook [11] - Analysts estimate that if Base issues tokens, it could create a market opportunity valued between $12 billion and $34 billion, with Coinbase's share estimated at $4 billion to $12 billion [12]

Core Insights - Coinbase CEO Brian Armstrong highlighted the potential of blockchain technology to streamline company registration, seed funding, and direct listings through equity tokenization, aiming for a more efficient, fair, and transparent capital formation process [1] - Wall Street responded positively, with JPMorgan upgrading Coinbase's stock rating to "overweight" and the stock price increasing by approximately 10% [1] Group 1: Financing Ecosystem - Coinbase plans to simplify the current cumbersome financing process by leveraging its recently acquired Echo platform, which has already helped over 200 projects raise over $200 million [3] - Echo will initially operate independently but will gradually integrate into Coinbase's ecosystem, connecting entrepreneurs seeking funding with Coinbase's $500 billion in managed assets and its global investor base [3] - Armstrong emphasized that connecting talented entrepreneurs with capital-holding investors positions Coinbase as an ideal platform to accelerate this process [3] Group 2: Regulatory Challenges - A key aspect of Coinbase's vision involves regulatory collaboration to promote broader access to on-chain financing [4] - Armstrong criticized existing accredited investor rules as unfair, as they exclude many individual investors from early investment opportunities [4] - Coinbase aims to find a balance between consumer protection and opening up these opportunities to retail investors, indicating a desire to change existing market access barriers [4] Group 3: Base Network Potential - Coinbase's on-chain strategy is closely linked to the development of its Layer-2 network, Base, which is a significant reason for the positive outlook from investment banks [5] - JPMorgan's report noted that the upgrade in Coinbase's rating was based on the substantial growth potential of the Base network and revised USDC reward strategies [6] - Analysts estimate that if Base issues tokens, it could create a market opportunity valued between $12 billion and $34 billion, with Coinbase's share estimated between $4 billion and $12 billion [6]

Group 1 - Coinbase Global has reached an acquisition agreement with Echo for approximately $375 million [1] - Echo is a platform that enables cryptocurrency companies to raise funds quickly on the blockchain [1]

Core Viewpoint - The strategic cooperation agreement between Huajian Medical and Chuangsheng Group aims to explore the tokenization of innovative drug pipeline assets valued at over $1.5 billion, focusing on six major oncology drug pipelines [1][2]. Group 1: Strategic Cooperation Details - Huajian Medical and Chuangsheng Group signed a strategic cooperation agreement to jointly explore the tokenization of innovative drug pipeline assets [1]. - The collaboration involves six innovative oncology drug pipelines, including TST003, TST005, TST786, and three preclinical antibody-drug conjugates TST105, TST106, and TST013 [1]. - These pipelines utilize advanced technologies such as bispecific antibodies, trispecific antibodies, ADCs, and fusion proteins, showcasing global innovation or best-in-class potential [1]. Group 2: Technological and Financial Aspects - Huajian Medical will provide a comprehensive technological solution covering digital initiation, trusted on-chain processes, compliant issuance, and liquidity integration for the pipeline assets [1]. - The cooperation is expected to lock in the R&D value of high-value pipelines, provide new channels for global capital allocation, and accelerate therapy accessibility [2].

Transcenta Holding Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 自願公告 有關與華檢醫療控股有限公司及其兩間子公司的戰略合作協議 探索首創真實世界資產代幣化潛在融資用於 創新腫瘤療法研發的業務進展 本公告由創勝集團醫藥有限公司（「本公司」）自願作出，旨在告知本公司股東及潛 在投資者有關最新業務進展。本公告所用但並無另行界定的詞彙應與本公司日期 為2021年9月14日的招股章程中所賦予該等詞彙的涵義相同。 本公司董事會（「董事會」）欣然公佈，於2025年9月21日，本公司及本公司全資子 公司Transcenta Oncology Inc.（「Transcenta Oncology」）已與華檢醫療控股有限 公司（香港聯合交易所有限公司主板上市公司，股份代號：1931）及其兩間子公司 ETHK Inc.及ETHK HOLDINGS L ...